Drugs / BIRCH TRITERPENES

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 24 trials
Phase 2 NCT05190770 Dec 2021 → Aug 2024 breast cancer Memorial Sloan Kettering Cancer Center Completed No outcome recorded
Phase 2 NCT01294241 Nov 2010 → Jun 2011 inherited epidermolysis bullosa Birken AG Completed No outcome recorded
Phase 2 NCT01294254 Apr → Nov 2010 Birken AG Completed No outcome recorded
Phase 2 NCT00786994 Oct 2008 → Nov 2010 actinic keratosis Birken AG Completed No outcome recorded
Phase 34 trials
Phase 3 NCT06917690 Apr 2025 → Mar 2026 overdue collagenopathy, epidermolysis bullosa dystrophica, junctional epidermolysis bullosa Chiesi Farmaceutici S.p.A. Recruiting No outcome recorded
Phase 3 NCT01807650 Mar → Sep 2013 Birken AG Completed No outcome recorded
Phase 3 NCT01657305 Aug 2012 → Aug 2013 Birken AG Completed No outcome recorded
Phase 3 NCT01657292 Aug 2012 → Jul 2013 Birken AG Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as BIRCH TRITERPENES ChEMBL registry synonym — accepted as the source's own label CHEMBL4650246
Known as Episalvan ChEMBL registry synonym — accepted as the source's own label CHEMBL4650246
Known as FIlsuVEz “Multi-centeR, Open-label Study to EValuate the Safety, Efficacy, and Pharmacokinetics of FIlsuVEz (Oleogel-S10) in Japanese Subjects With Epidermolysis Bullosa (REVIVE)” NCT06917690
Known as Oleogel-S10 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01657292
7

NCT01807650

NCT06917690

NCT01294241

NCT01294254

NCT05190770

NCT00786994

NCT01657305

Modality Small molecule CHEMBL4650246
Route Topical “Patients (n = 165) were treated topically for 3 months” PMID 25124939 Feb 2015